Plerixafor for Patients Failing Stem Cell Mobilization: A Review of the Clinical and Cost-Effectiveness and Guidelines [Internet].

In 2012, the CADTH Common Drug Review (CDR) examined the evidence on plerixafor, consisting of two randomized controlled trials, and issued a "do not list" recommendation based on the exclusion of the subpopulation of interest from the included studies (i.e. predicted poor or proven poor mobilizers). This Rapid Response report aims to identify and review the clinical and cost-effectiveness of plerixafor in patients who are failing stem cell mobilization. Guidelines associated with the use of plerixafor in patients failing stem cell mobilization will also be examined.

http://ift.tt/2kPYhfF